15-Year watch begins for CAR t cell therapy patients
NCT ID NCT04911478
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 50 people who have already received an experimental CAR T cell therapy for certain blood cancers like lymphoma. No new treatment is given; instead, researchers will check for long-term side effects and how well the therapy works over 15 years. The goal is to better understand the lasting safety and effectiveness of this approach.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Baylor Scott & White Research Institute
Dallas, Texas, 75204, United States
-
Blood and Marrow Transplant Program
Palo Alto, California, 94304, United States
-
MD Anderson Caner Center
Houston, Texas, 77030, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Norton Cancer Institute
Louisville, Kentucky, 40207, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can donor immune cells be engineered to fight blood cancer?